Caeli Nova raises CHF 8 million in Series A funding to deliver new emergency oxygen system onto passenger aircraft

Caeli Nova, innovating at the intersection of aviation and healthcare, has successfully closed its Series A round of financing. This latest round of investment will allow the breathing technology developer to take greater strides in enhancing its technology and to bring its first products to the market.

Cordillera, Caeli Nova’s launch product, is an advanced aircraft emergency oxygen system that overcomes limitations associated with the existing technology, while significantly reducing costs and carbon emissions for airlines by enabling aircraft to fly the most direct routes. The company is aiming to install Cordillera onto first aircraft during 2022.

LG Capital, the Switzerland-based venture builder and co-founder of Caeli Nova, spearheaded the company’s CHF 8 million Series A financing round, which has drawn investments from both the healthcare as well as the aviation sectors. The round was led by principal investor Ornament Health, a Swiss digital health company. Other primary financing partners participating in this round included Latécoère, a leading stock market listed Tier 1 aerospace manufacturer. (£1.00 = CHF1.24 at time of publication)

Email Post to a Friend Email Post to a Friend